LAUSR

Abstract Low and high serum retinol levels are associated with increased fracture risk and poor bone health. We recently showed retinoic acid receptors (RARs) are negative regulators of osteoclastogenesis. Here we show RARs are also negative regulators of osteoblast and adipocyte differentiation. The pan‐RAR agonist, all‐trans retinoic acid (ATRA), directly inhibited differentiation and mineralisation of early osteoprogenitors and impaired the differentiation of more mature osteoblast populations. In contrast, the pan‐RAR antagonist, IRX4310, accelerated differentiation of early osteoprogenitors. These effects predominantly occurred via RAR&ggr; and were further enhanced by an RAR&agr; agonist or antagonist, respectively. RAR agonists similarly impaired adipogenesis in osteogenic cultures. RAR agonist treatment resulted in significant upregulation of the Wnt antagonist, Sfrp4. This accompanied reduced nuclear and cytosolic &bgr;‐catenin protein and reduced expression of the Wnt target gene Axin2, suggesting impaired Wnt/&bgr;‐catenin signalling. To determine the effect of RAR inhibition in post‐natal mice, IRX4310 was administered to male mice for 10 days and bones were assessed by &mgr;CT. No change to trabecular bone volume was observed, however, radial bone growth was impaired. These studies show RARs directly influence osteoblast and adipocyte formation from mesenchymal cells, and inhibition of RAR signalling in vivo impairs radial bone growth in post‐natal mice. Graphical abstract Schematic shows RAR ligand regulation of osteoblast differentiation in vitro. RAR&ggr; antagonists±RAR&agr; antagonists promote osteoblast differentiation. RAR&ggr; and RAR&agr; agonists alone or in combination block osteoblast differentiation, which correlates with upregulation of Sfrp4, and downregulation of nuclear and cytosolic &bgr;‐catenin and reduced expression of the Wnt target gene Axin2. Red arrows indicate effects of RAR agonists on mediators of Wnt signalling. Figure. No Caption available.